Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Samsung Biologics Co.,Ltd. (207940.KS)

KSE - KSE Delayed Price. Currency in KRW
Add to watchlist
881,000.00+4,000.00 (+0.46%)
As of 12:07PM KST. Market open.
Advertisement

Samsung Biologics Co.,Ltd.

300, Songdo Bio-daero
Yeonsu-gu
Incheon 21987
South Korea
82 3 2455 3114
http://samsungbiologics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees2,886

Key Executives

NameTitlePayExercisedYear Born
Mr. John Chongbo RimCEO, Pres & Director1.09BN/A1961
Mr. James J. ChoiChief Information Officer and VP569MN/A1967
Dr. Kyusung LeeExec. VP of Gen. Manufacturing Technology993MN/A1960
Yoon KwanghunExec. VP1.03BN/AN/A
Mr. Dong-Joong KimCFO, Sr. VP, MD & DirectorN/AN/A1965
Hyung Woo MoonCompliance OfficerN/AN/AN/A
Mr. Andy Yongsin KimCHRO & VPN/AN/A1964
Mr. Hoyeol YoonSr. VPN/AN/A1963
Mr. James ParkSr. VP, MD & CBON/AN/A1966
Mr. Gwanghun YunExec. VP of Gen. plant, Construction & InfrastructureN/AN/A1956
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.

Description

Samsung Biologics Co., Ltd. engages in the contract manufacturing organization business for biopharmaceuticals products. It is involved in the provision of contract development organization services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company has a strategic partnership agreement with Kineta, Inc. Samsung Biologics Co., Ltd. was founded in 2011 and is headquartered in Incheon, South Korea.

Corporate Governance

Samsung Biologics Co.,Ltd.’s ISS Governance QualityScore as of September 26, 2021 is 8. The pillar scores are Audit: 5; Board: 3; Shareholder Rights: 10; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement